Van Lanschot Kempen Investment Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $18M | Buy |
71,684
+2,708
| +4% | +$583K | 0.14% | 113 |
|
|
2026
Q1 | $15M | Buy |
68,976
+40,208
| +140% | +$8.92M | 0.13% | 117 |
|
|
2025
Q4 | $6.57M | Sell |
28,768
-20,426
| -42% | -$4.65M | 0.06% | 189 |
|
|
2025
Q3 | $11.4M | Sell |
49,194
-5,229
| -10% | -$1.06M | 0.1% | 145 |
|
|
2025
Q2 | $10.1M | Buy |
54,423
+16,292
| +43% | +$3.03M | 0.1% | 152 |
|
|
2025
Q1 | $7.99M | Buy |
38,131
+1,652
| +5% | +$321K | 0.08% | 159 |
|
|
2024
Q4 | $6.48M | Sell |
36,479
-459
| -1% | -$84.4K | 0.06% | 162 |
|
|
2024
Q3 | $7.29M | Sell |
36,938
-636
| -2% | -$119K | 0.07% | 147 |
|
|
2024
Q2 | $6.44M | Buy |
37,574
+5,073
| +16% | +$840K | 0.07% | 149 |
|
|
2024
Q1 | $5.92M | Buy |
32,501
+7,369
| +29% | +$1.27M | 0.07% | 151 |
|
|
2023
Q4 | $3.89M | Buy |
25,132
+3,041
| +14% | +$443K | 0.05% | 158 |
|
|
2023
Q3 | $3.29M | Buy |
22,091
+20,175
| +1,053% | +$2.96M | 0.06% | 138 |
|
|
2023
Q2 | $258K | Buy |
+1,916
| New | +$281K | ﹤0.01% | 188 |
|
|
2021
Q2 | – | Sell |
-17,941
| Closed | -$1.94M | – | 203 |
|
|
2021
Q1 | $1.94M | Buy |
17,941
+2,385
| +15% | +$255K | 0.09% | 123 |
|
|
2020
Q4 | $1.67M | Sell |
15,556
-4,840
| -24% | -$465K | 0.1% | 123 |
|
|
2020
Q3 | $1.79M | Buy |
20,396
+1,005
| +5% | +$94.6K | 0.14% | 107 |
|
|
2020
Q2 | $1.9M | Buy |
19,391
+4,724
| +32% | +$416K | 0.14% | 106 |
|
|
2020
Q1 | $1.12M | Buy |
14,667
+845
| +6% | +$72K | 0.09% | 119 |
|
|
2019
Q4 | $1.22M | Buy |
13,822
+13,253
| +2,329% | +$1.1M | 0.08% | 128 |
|
|
2019
Q3 | $43K | Hold |
569
| – | – | ﹤0.01% | 170 |
|
|
2019
Q2 | $41K | Buy |
+569
| New | +$44.7K | ﹤0.01% | 174 |
|
|
2017
Q4 | – | Sell |
-316,850
| Closed | -$28.2M | – | 156 |
|
|
2017
Q3 | $28.2M | Sell |
316,850
-13,050
| -4% | -$993K | 2.18% | 6 |
|
|
2017
Q2 | $23.9M | Sell |
329,900
-34,800
| -10% | -$2.34M | 2.26% | 14 |
|
|
2017
Q1 | $23.8M | Buy |
364,700
+22,400
| +7% | +$1.41M | 2.74% | 13 |
|
|
2016
Q4 | $21.4M | Buy |
342,300
+26,950
| +9% | +$1.65M | 2.68% | 13 |
|
|
2016
Q3 | $19.9M | Buy |
+315,350
| New | +$20.4M | 2.58% | 17 |
|
|
2015
Q4 | – | Sell |
-19,200
| Closed | -$1.04M | – | 140 |
|
|
2015
Q3 | $1.04M | Sell |
19,200
-2,000
| -9% | -$130K | 0.13% | 88 |
|
|
2015
Q2 | $1.42M | Buy |
21,200
+3,000
| +16% | +$196K | 0.16% | 71 |
|
|
2015
Q1 | $1.06M | Buy |
+18,200
| New | +$1.1M | 0.13% | 76 |
|
|
2014
Q4 | – | Sell |
-572,192
| Closed | -$33M | – | 134 |
|
|
2014
Q3 | $33M | Sell |
572,192
-82,100
| -13% | -$4.56M | 3.45% | 11 |
|
|
2014
Q2 | $36.9M | Buy |
+654,292
| New | +$34.3M | 3.58% | 8 |
|
Other funds holding ABBV
Van Lanschot Kempen Investment Management's ABBV Position: Q2 2026 in Review
Van Lanschot Kempen Investment Management increased its AbbVie (ABBV) stake by 3.9% in Q2 2026, buying an estimated $583K and bringing the position to 71,684 shares worth $18M. The position accounts for 0.14% of the portfolio, ranked #113.
Van Lanschot Kempen Investment Management first reported a position in ABBV in Q2 2014 and has held it in 31 quarters since. The position peaked at $36.9M in Q2 2014. 4,190 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Van Lanschot Kempen Investment Management held 71,684 shares of AbbVie worth $18M as of Q2 2026.
- Van Lanschot Kempen Investment Management bought 2,708 AbbVie shares in Q2 2026, an estimated $583K.
- AbbVie made up 0.14% of Van Lanschot Kempen Investment Management's portfolio in Q2 2026, its #113 holding.
- Van Lanschot Kempen Investment Management first reported a position in AbbVie in Q2 2014 and has held it in 31 quarters since.
- Van Lanschot Kempen Investment Management's AbbVie position peaked at $36.9M in Q2 2014.
- 4,190 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Van Lanschot Kempen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.